Brightworth cut its stake in Becton Dickinson and Co (NYSE:BDX) by 1.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 29,048 shares of the medical instruments supplier’s stock after selling 294 shares during the quarter. Becton Dickinson and comprises about 1.5% of Brightworth’s holdings, making the stock its 17th largest position. Brightworth’s holdings in Becton Dickinson and were worth $6,545,000 as of its most recent SEC filing.
Several other large investors also recently made changes to their positions in the company. Chartwell Investment Partners LLC lifted its holdings in shares of Becton Dickinson and by 26.9% in the 4th quarter. Chartwell Investment Partners LLC now owns 9,477 shares of the medical instruments supplier’s stock valued at $2,135,000 after buying an additional 2,006 shares during the period. Beach Investment Counsel Inc. PA grew its position in shares of Becton Dickinson and by 4.4% in the fourth quarter. Beach Investment Counsel Inc. PA now owns 60,973 shares of the medical instruments supplier’s stock valued at $15,210,000 after purchasing an additional 2,570 shares in the last quarter. Beach Investment Management LLC. grew its position in shares of Becton Dickinson and by 10.9% in the fourth quarter. Beach Investment Management LLC. now owns 5,090 shares of the medical instruments supplier’s stock valued at $1,147,000 after purchasing an additional 500 shares in the last quarter. South Texas Money Management Ltd. grew its position in shares of Becton Dickinson and by 3.3% in the fourth quarter. South Texas Money Management Ltd. now owns 3,318 shares of the medical instruments supplier’s stock valued at $748,000 after purchasing an additional 107 shares in the last quarter. Finally, TD Asset Management Inc. grew its position in Becton Dickinson and by 1.4% in the fourth quarter. TD Asset Management Inc. now owns 488,897 shares of the medical instruments supplier’s stock worth $110,158,000 after acquiring an additional 6,607 shares during the period. Institutional investors and hedge funds own 83.84% of the company’s stock.
In other Becton Dickinson and news, EVP Ribo Alberto Mas sold 4,530 shares of the stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $237.01, for a total value of $1,073,655.30. Following the completion of the sale, the executive vice president now owns 14,596 shares in the company, valued at approximately $3,459,397.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP James W. Borzi sold 5,887 shares of the stock in a transaction on Friday, November 30th. The stock was sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the transaction, the executive vice president now owns 6,013 shares in the company, valued at approximately $1,517,500.81. The disclosure for this sale can be found here. Over the last three months, insiders have sold 34,606 shares of company stock valued at $8,356,772. Company insiders own 0.12% of the company’s stock.
Shares of Becton Dickinson and stock opened at $242.21 on Friday. The stock has a market capitalization of $64.99 billion, a PE ratio of 22.00, a P/E/G ratio of 1.70 and a beta of 1.23. The company has a current ratio of 0.97, a quick ratio of 0.69 and a debt-to-equity ratio of 0.83. Becton Dickinson and Co has a 1 year low of $208.62 and a 1 year high of $265.87.
Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The business had revenue of $4.16 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter in the prior year, the firm earned $2.48 EPS. The company’s revenue for the quarter was up 35.1% compared to the same quarter last year. Sell-side analysts forecast that Becton Dickinson and Co will post 12.1 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.27%. The ex-dividend date of this dividend is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.
A number of research analysts have commented on BDX shares. TheStreet upgraded Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday. Zacks Investment Research upgraded Becton Dickinson and from a “hold” rating to a “buy” rating and set a $243.00 price target on the stock in a research note on Tuesday, January 8th. Citigroup cut their price target on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a research note on Tuesday, November 13th. Deutsche Bank started coverage on Becton Dickinson and in a report on Thursday, December 6th. They set a “buy” rating and a $280.00 price objective on the stock. Finally, Barclays began coverage on Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 price objective on the stock. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Becton Dickinson and presently has an average rating of “Buy” and a consensus price target of $253.17.
TRADEMARK VIOLATION WARNING: “Becton Dickinson and Co (BDX) Shares Sold by Brightworth” was first posted by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://macondaily.com/2019/02/09/becton-dickinson-and-co-bdx-shares-sold-by-brightworth.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Read More: Correction
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.